SCHEMBL6791102

SCHEMBL6791102

CC(=O)Oc1ccc(-c2ccc(C(O)C3(C)NC(=O)NC3=O)cc2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.42
LMNA P02545 4/20 0.37
GAA P10253 1/20 0.37
MAPT P10636 3/20 0.37
KDM4E B2RXH2 1/20 0.36
ABCB11 O95342 1/20 0.36
ESR1 P03372 1/20 0.36
CYP3A4 P08684 1/20 0.36
ADRA2A P08913 1/20 0.36
CYP2C9 P11712 1/20 0.36
TSHR P16473 1/20 0.36
PDE4A P27815 1/20 0.36
ADRA1A P35348 1/20 0.36
OPRK1 P41145 1/20 0.36
STAT6 P42226 1/20 0.36
SLC6A3 Q01959 1/20 0.36
HIF1A Q16665 1/20 0.36
GPR55 Q9Y2T6 1/20 0.36
TDP1 Q9NUW8 1/20 0.35
POLB P06746 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6786669 0.88 MAPT (0.41) LMNAGAAMAPTCYP3A4TDP1
SCHEMBL6793983 0.85 MMP2 (0.45) LMNACYP3A4ALDH1A1MAPK1NPSR1
SCHEMBL6791153 0.81 MMP2 (0.41) MAPTCYP3A4CYP2C9SLC6A3PTGS2
SCHEMBL6791227 0.81 MMP2 (0.41) MAPTCYP3A4CYP2C9SLC6A3PTGS2
SCHEMBL6793526 0.80 CA12 (0.40) HSD17B10MMP2MMP9MMP8
SCHEMBL6790247 0.80 SMN1; SMN2 (0.49) MAPTKDM4ECYP3A4TSHRTDP1
SCHEMBL6792387 0.77 MMP2 (0.45) PTGS2RAB9AMMP2MMP9MMP8
SCHEMBL6827181 0.76 ESR1 (0.44) ESR1CYP3A4CYP2C9CYP19A1
SCHEMBL6824389 0.76 CA2 (0.41) LMNAGAAKDM4EALDH1A1HPGD
SCHEMBL6701363 0.75 MMP2 (0.31) MMP2MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040147573-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-07-29 US disclosed
US-20040110809-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-06-10 US disclosed
EP-1370538-A1 METALLOPROTEINASE INHIBITORS AstraZeneca AB (SE) 2003-12-17 EP disclosed
WO-2002074752-A1 METALLOPROTEINASE INHIBITORS ASTRAZENECA AB (SE) 2002-09-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110809-A1 Metalloproteinase inhibitors MMP9, MMP2, MMP3 HSD17B10 456/4885LMNA 1493/4885GAA 274/4885
US-20040147573-A1 Metalloproteinase inhibitors MMP12, MMP7, MMP10 HSD17B10 174/4885LMNA 2465/4885GAA 408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.